companydata.dkEvodiaBio ApS: Financial statements 2022
CVR: 42569283
EvodiaBio ApS (CVR 42569283) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -2,943,103 and a net result of DKK -6,304,639. Equity amounted to DKK 37,682,422. The solvency ratio was 97.9%. The company had 7 employees in the financial year.
- Gross Profit
- -2,943,103 kr.
- Profit/Loss
- -6,304,639 kr.
- Equity
- 37,682,422 kr.
- Total Assets
- 38,487,276 kr.
- Employees
- 7
Keep an eye on EvodiaBio ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of December 19, 2022, Lauri Johannes Reuter has joined the board of directors of EvodiaBio ApS.
As of December 19, 2022, Bart Van Hooland has joined the board of directors of EvodiaBio ApS.
EvodiaBio ApS has published its interim report for the period July 28, 2021 – December 31, 2021.
As of June 28, 2022, Flemming Besenbacher has joined the board of directors of EvodiaBio ApS.
As of June 28, 2022, Andreas Helmut Fibig has joined the board of directors of EvodiaBio ApS.
As of June 28, 2022, Anne Françoise Véronique Cabotin has joined the board of directors of EvodiaBio ApS.
As of June 28, 2022, Victor Forman has left the board of directors of EvodiaBio ApS.
As of June 28, 2022, Simon Louis Théodore Armand Dusséaux has left the board of directors of EvodiaBio ApS.
About EvodiaBio ApS
EvodiaBio ApS is a Danish company of the type Anpartsselskab based in Rødovre, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Camilla Benedicte Kloss Fenneberg. The company's owners include Jarne Elleholm, BII Holdings A/S and FormanBiotech Holding ApS. In 2025, the company reported a gross profit of DKK -8,437,110 and a net result of DKK -26,798,122 compared with DKK -21,106,598 the year before. Equity amounted to DKK 68,626,121.